GSK Steps Up Bid for Human Genome Sciences

May 30, 2012

May 31, 2012 | GlaxoSmithKline is hoping to replace the board of Human Genome Sciences with its own representatives, reaching out to executives who could be nominated as "independent" directors. GSK made a $2.6 billion hostile bid for Human Genome Sciences that it set to expire June 7, though may be extended. CNBC